Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL662165 | 0.88 | MAOA (0.49) | NR4A2MAOAMAOBTRPV1RAB9A | |
| SCHEMBL662164 | 0.88 | MAOA (0.49) | NR4A2MAOAMAOBTRPV1RAB9A | |
| SCHEMBL10185462 | 0.87 | DGAT1 (0.55) | DGAT1CHRM4RAB9ANPC1HSD17B10 | |
| SCHEMBL664113 | 0.86 | DGAT1 (0.56) | DGAT1RAB9ANPC1HSD17B10 | |
| SCHEMBL664114 | 0.86 | DGAT1 (0.56) | DGAT1RAB9ANPC1HSD17B10 | |
| SCHEMBL10184323 | 0.86 | DGAT1 (0.56) | DGAT1RAB9ANPC1HSD17B10 | |
| SCHEMBL10184881 | 0.85 | DGAT1 (0.50) | DGAT1RAB9ANPC1HSD17B10 | |
| SCHEMBL10186476 | 0.84 | SMN1; SMN2 (0.54) | NR4A2MAOAMAOBDGAT1CHRM4 | |
| SCHEMBL10184403 | 0.84 | DGAT1 (0.54) | DGAT1HSD17B10 | |
| SCHEMBL663534 | 0.84 | DGAT1 (0.49) | MAOBDGAT1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | NR4A2 2671/4885MAOA 1968/4885MAOB 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.